Testing of the predictive role of PD-L1 expression in glioblastoma samples collected in the ongoing trials will need careful consideration of assay validation, cut-off definitions and evaluation criteria to provide meaningful and clinically relevant results. This evidence concerns the gene CD274 and glioblastoma.